Here's the skinny: Inpellis files for a $20 million IPO

Inpellis, which is developing transdermal pain treatments for musculoskeletal disorders, filed on Thursday with the SEC to raise up to $20 million in an initial public offering.

The Haddonfield, NJ-based company, which was founded in 2012 and booked n/a in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol INPL. Inpellis filed confidentially on 4/9/2015. Alexander Capital is the sole bookrunner on the deal. No pricing terms were disclosed.